Response surface methodology optimizes selenium inhibition of prostate cancer PC-3 cell viability
Copyright © 2024 Elsevier GmbH. All rights reserved..
BACKGROUND: The rising incidence of prostate cancer in the U.S. necessitates innovative therapeutic approaches to this disease. Though extensive research has studied Selenium as an anticarcinogen against prostate cancer, results have varied due to overlooked experimental confounds. Recent studies have identified differential effects of various selenium compounds on prostate cancer cells. This study leverages Mixture Design Response Surface Methodology to characterize the ideal combination of select Se forms against the PC-3 prostate cancer cell line.
METHODS: The PC-3 cell line was chosen as a model for its representation of advanced-stage malignancy. Three Se compounds-sodium selenite, methylseleninic acid, and nano-selenium-were selected for their promising antineoplastic potential. Nano-Se particles were synthesized and subsequently characterized by transmission electron microscopy. Cells were cultured, treated with Se compounds, and assessed for viability using an Alamar Blue Assay. IC50 values of individual Se compounds were determined, and treatment combinations evaluated. In collaboration with statical modeling experts, MDRSM was utilized to optimize Se compound combinations.
RESULTS: Absolute IC50 values were identified for methylseleninic acid (5.01 μmol/L), sodium selenite (13.8 μmol/L), and nano-selenium (14.6 μmol/L). Combining methylseleninic acid and sodium selenite resulted in only 5% PC-3 cell viability, whereas individual treatments reduced viability by approximately 45%. Among the tested mixtures, the 50:50 combination of MSA and sodium selenite most effectively decreased PC-3 cell viability. Regression analysis indicated the special cubic model had a strong fit (multiple r² = 0.9853), predicting maximum cell viability reduction from the methylseleninic acid and selenite mixture.
CONCLUSION: The specific form of Selenium plays a pivotal role in determining its physiological effects and therapeutic potential against prostate cancer. All three selenium compounds showed variable antineoplastic effects, with a 50:50 mixture of methylseleninic acid and selenite exhibiting optimal results. Nano-selenium, when combined with selenite, showed no additive effect, implying a shared mechanism of action. Our research underscores the critical need to consider Se compound forms as distinct entities in prostate cancer treatment and encourages further exploration of Se compounds against prostate cancer.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:84 |
|---|---|
| Enthalten in: |
Journal of trace elements in medicine and biology : organ of the Society for Minerals and Trace Elements (GMS) - 84(2024) vom: 28. Feb., Seite 127414 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Whitcomb, Andrew [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Cell Viability |
|---|
| Anmerkungen: |
Date Revised 15.03.2024 published: Print-Electronic Citation Status Publisher |
|---|
| doi: |
10.1016/j.jtemb.2024.127414 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM369796020 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM369796020 | ||
| 003 | DE-627 | ||
| 005 | 20240316233300.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240316s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.jtemb.2024.127414 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1332.xml |
| 035 | |a (DE-627)NLM369796020 | ||
| 035 | |a (NLM)38489924 | ||
| 035 | |a (PII)S0946-672X(24)00034-8 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Whitcomb, Andrew |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Response surface methodology optimizes selenium inhibition of prostate cancer PC-3 cell viability |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 15.03.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status Publisher | ||
| 520 | |a Copyright © 2024 Elsevier GmbH. All rights reserved. | ||
| 520 | |a BACKGROUND: The rising incidence of prostate cancer in the U.S. necessitates innovative therapeutic approaches to this disease. Though extensive research has studied Selenium as an anticarcinogen against prostate cancer, results have varied due to overlooked experimental confounds. Recent studies have identified differential effects of various selenium compounds on prostate cancer cells. This study leverages Mixture Design Response Surface Methodology to characterize the ideal combination of select Se forms against the PC-3 prostate cancer cell line | ||
| 520 | |a METHODS: The PC-3 cell line was chosen as a model for its representation of advanced-stage malignancy. Three Se compounds-sodium selenite, methylseleninic acid, and nano-selenium-were selected for their promising antineoplastic potential. Nano-Se particles were synthesized and subsequently characterized by transmission electron microscopy. Cells were cultured, treated with Se compounds, and assessed for viability using an Alamar Blue Assay. IC50 values of individual Se compounds were determined, and treatment combinations evaluated. In collaboration with statical modeling experts, MDRSM was utilized to optimize Se compound combinations | ||
| 520 | |a RESULTS: Absolute IC50 values were identified for methylseleninic acid (5.01 μmol/L), sodium selenite (13.8 μmol/L), and nano-selenium (14.6 μmol/L). Combining methylseleninic acid and sodium selenite resulted in only 5% PC-3 cell viability, whereas individual treatments reduced viability by approximately 45%. Among the tested mixtures, the 50:50 combination of MSA and sodium selenite most effectively decreased PC-3 cell viability. Regression analysis indicated the special cubic model had a strong fit (multiple r² = 0.9853), predicting maximum cell viability reduction from the methylseleninic acid and selenite mixture | ||
| 520 | |a CONCLUSION: The specific form of Selenium plays a pivotal role in determining its physiological effects and therapeutic potential against prostate cancer. All three selenium compounds showed variable antineoplastic effects, with a 50:50 mixture of methylseleninic acid and selenite exhibiting optimal results. Nano-selenium, when combined with selenite, showed no additive effect, implying a shared mechanism of action. Our research underscores the critical need to consider Se compound forms as distinct entities in prostate cancer treatment and encourages further exploration of Se compounds against prostate cancer | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Cell Viability | |
| 650 | 4 | |a Methylseleninic Acid | |
| 650 | 4 | |a Mixture Design | |
| 650 | 4 | |a Nano-Selenium | |
| 650 | 4 | |a PC-3 | |
| 650 | 4 | |a Prostate Cancer | |
| 650 | 4 | |a Response Surface Methodology | |
| 650 | 4 | |a Selenium | |
| 650 | 4 | |a Sodium Selenite | |
| 650 | 4 | |a Special Cubic Model | |
| 700 | 1 | |a Li, Xiuqi |e verfasserin |4 aut | |
| 700 | 1 | |a Lawson, John |e verfasserin |4 aut | |
| 700 | 1 | |a Christensen, Merrill |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of trace elements in medicine and biology : organ of the Society for Minerals and Trace Elements (GMS) |d 1997 |g 84(2024) vom: 28. Feb., Seite 127414 |w (DE-627)NLM085797529 |x 1878-3252 |7 nnns |
| 773 | 1 | 8 | |g volume:84 |g year:2024 |g day:28 |g month:02 |g pages:127414 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.jtemb.2024.127414 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 84 |j 2024 |b 28 |c 02 |h 127414 | ||